Financial Comparison
Merck & Co., Inc. vs Pfizer Inc
Click a ticker to view the full analysis.
MRK vs
In short
Merck & Co., Inc. is the more profitable of the two, keeping 28.1% of revenue as net profit against 12.4% for Pfizer Inc. Merck & Co., Inc. trades at the higher trailing P/E (113.0× vs 36.6× for Pfizer Inc), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Merck & Co., Inc. and 1 for Pfizer Inc.
Based on filings for periods ending 30 Jun 2026 (MRK) and 28 Jun 2026 (PFE) · Updated
FisclearScore Comparison
MRK55Fair
PFE61Fair
Quality
53
53
Efficiency+5
50
55
Value+10
62
72
Cashflow+27
53
80
Regime
55
55
Peers+6
56
50
FisclearScore is a quantitative model. MRK shown solid · PFE shown dashed. Not financial advice.
| Metric | MRK | PFE |
|---|---|---|
| Price | $142.38 | $27.82 |
| Market Cap | $351.3B | $158.6B |
| P/E (TTM) | 113.0x | 36.6x |
| P/B | 8.4x | 1.9x |
| Beta | 0.22 | 0.28 |
| Div Yield | 2.34% | 6.06% |
| Revenue (TTM) | $65.0B | $62.6B |
| Net Income | $18.3B | $7.8B |
| Gross Margin | — | — |
| Risk Flags | 1 flag | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.